Honma et al. [7] first reported that the downregulation of RPN2 gene induces apoptosis in docetaxel-resistant breast cancer cells in the presence of docetaxel, indicating that RPN2 might be a new target for patients who show poor response to treatment with docetaxel-based neoadjuvant or adjuvant chemotherapy. The gene discussed is RPN2; the disease is breast cancer.